ZYNEX INC
ZYXIQOTCHealthcare · Electromedical & Electrotherapeutic Apparatus · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $192.4M | $184.3M | $158.2M | $24.1M | $15.2M | $9.2M |
| Operating income | $6.0M | $10.8M | $22.9M | −$1.1M | $2.5M | $2.3M |
| Net income | $3.0M | $9.7M | $17.0M | −$706,000 | $2.9M | $2.4M |
| Total assets | $122.1M | $136.9M | $116.5M | $133.3M | $72.2M | $28.3M |
| Total liabilities | $86.4M | $90.8M | $50.1M | $59.3M | $15.3M | $8.6M |
| Equity | $35.7M | $46.1M | $66.4M | $73.9M | $56.9M | $19.7M |
| EPS (diluted) | $0.09 | $0.27 | $0.44 | $0.44 | $0.24 | $0.28 |
| Shares out. | 32.2M | 36.6M | 39.8M | 34.8M | 32.8M | 32.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- 3.1%
- Net margin
- 1.6%
- Return on equity
- 8.4%
- Return on assets
- 2.5%
- Return on capital (ROCE)
- 5.7%
- Liabilities / assets
- 70.8%
- Debt / equity
- 2.42×
- Book value / share
- $1.11
- Revenue growth (YoY)
- 4.4%
- Net income growth (YoY)
- −69.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- 4.69safe
- Accruals / assets
- −8.0%clean
- Beneish M-Score
- -3.18normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 5 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 12, 2025
- NT 10-Qmissed a reporting deadline ↗May 16, 2017
- NT 10-Kmissed a reporting deadline ↗Apr 3, 2017
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2016
- NT 10-Qmissed a reporting deadline ↗May 17, 2016
- NT 10-Qmissed a reporting deadline ↗Nov 17, 2015
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Mar 13, 2026 | 1.2M | 7.8 | +1.0% |
| Feb 27, 2026 | 1.2M | 4.4 | +3.1% |
| Feb 13, 2026 | 1.1M | 9.1 | -2.3% |
| Jan 30, 2026 | 1.2M | 4.0 | +0.1% |
| Jan 15, 2026 | 1.2M | 4.4 | -37.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · New financial obligation · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 26, 2026
- Bankruptcy or receivershipMar 20, 2026
- Other material eventFeb 19, 2026
- Entered a material agreement · Regulation FD disclosureFeb 18, 2026
- Bankruptcy or receivershipFeb 11, 2026
- Bankruptcy or receivershipFeb 2, 2026
- Director / officer change · Regulation FD disclosureJan 23, 2026
- Entered a material agreement · Bankruptcy or receivership · New financial obligationJan 15, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.